The Safety of JAK-1 Inhibitors

Overview

Journal Rheumatology (Oxford)

Publisher Oxford University Press

Specialty Rheumatology

Date 2021 May 5

PMID 33950230

Citations 41

Authors

Benjamin Clarke

Mark Yates

Maryam Adas

Katie Bechman

James Galloway

Affiliations

Soon will be listed here.

Abstract

As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; monitoring for laboratory abnormalities, including lipids and muscle enzymes, is indicated. A distinguishing feature of JAK inhibitors is a risk for zoster reactivation. Numerically, overall rates of serious infection are similar among JAK inhibitor classes. There are currently no signals for diverticular perforation. VTE incidence rates were similar across comparator groups for the JAK1 selective agents. These observations are not yet conclusive evidence for different safety profiles between JAK1 selective agents and other JAK inhibitors. Differences in study population, design, and concomitant steroid use are examples of potential confounders. It is too early to draw conclusions on long-term outcomes such as malignancy and cardiovascular risk. Post-marketing pharmacovigilance studies will be essential.

Citing Articles

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.

Kanda R, Miyazaki Y, Nakayamada S, Fukuyo S, Kubo S, Miyagawa I Rheumatol Ther. 2025; .

PMID: 40025347 DOI: 10.1007/s40744-025-00747-9.

Flavonoids as Natural Anti-Inflammatory Agents in the Atopic Dermatitis Treatment.

Zawawi N, Ahmad H, Madatheri R, Fadilah N, Maarof M, Fauzi M Pharmaceutics. 2025; 17(2).

PMID: 40006628 PMC: 11859288. DOI: 10.3390/pharmaceutics17020261.

JAK inhibitors: a new choice for diabetes mellitus?.

Zhou M, Shen Q, Li B Diabetol Metab Syndr. 2025; 17(1):33.

PMID: 39849637 PMC: 11755809. DOI: 10.1186/s13098-025-01582-2.

Continuous Treatment with Tofacitinib but Not Filgotinib Is Effective in Non-Responders with Active Ulcerative Colitis: A Propensity Score-Matching Analysis.

Yagi S, Fukui H, Ikenouchi M, Shiraishi T, Kaku K, Wakita M J Clin Med. 2025; 14(1.

PMID: 39797304 PMC: 11721360. DOI: 10.3390/jcm14010217.

Therapeutic potential of antibody-drug conjugates possessing bifunctional anti-inflammatory action in the pathogenies of rheumatoid arthritis.

Dixit T, Vaidya A, Ravindran S Arthritis Res Ther. 2024; 26(1):216.

PMID: 39695738 PMC: 11656801. DOI: 10.1186/s13075-024-03452-0.

References

Cunningham A, Lal H, Kovac M, Chlibek R, Hwang S, Diez-Domingo J . Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016; 375(11):1019-32. DOI: 10.1056/NEJMoa1603800. View

Burmester G, Kremer J, Van den Bosch F, Kivitz A, Bessette L, Li Y . Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391(10139):2503-2512. DOI: 10.1016/S0140-6736(18)31115-2. View

Smolen J, Genovese M, Takeuchi T, Hyslop D, Macias W, Rooney T . Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. J Rheumatol. 2018; 46(1):7-18. DOI: 10.3899/jrheum.171361. View

Westhovens R, Taylor P, Alten R, Pavlova D, Enriquez-Sosa F, Mazur M . Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN.... Ann Rheum Dis. 2016; 76(6):998-1008. DOI: 10.1136/annrheumdis-2016-210104. View

Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H . Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020; 79(11):1400-1413. PMC: 7569391. DOI: 10.1136/annrheumdis-2019-216761. View

Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W . Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2016; 76(3):504-510. PMC: 5445993. DOI: 10.1136/annrheumdis-2016-209773. View

Miyakawa Y, Oda A, Druker B, Miyazaki H, Handa M, Ohashi H . Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood. 1996; 87(2):439-46. View

Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V . Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis. Arthritis Rheumatol. 2020; 73(5):779-788. DOI: 10.1002/art.41580. View

Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope A . A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019; 58(10):1755-1766. DOI: 10.1093/rheumatology/kez087. View

10.

Wollenhaupt J, Silverfield J, Lee E, Curtis J, Wood S, Soma K . Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014; 41(5):837-52. DOI: 10.3899/jrheum.130683. View

11.

Samuelson B, Vesely S, Chai-Adisaksopha C, Scott B, Crowther M, Garcia D . The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis. 2015; 27(6):648-52. DOI: 10.1097/MBC.0000000000000446. View

12.

Cunningham A, Heineman T, Lal H, Godeaux O, Chlibek R, Hwang S . Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. J Infect Dis. 2018; 217(11):1750-1760. PMC: 5946839. DOI: 10.1093/infdis/jiy095. View

13.

Castagne B, Viprey M, Martin J, Schott A, Cucherat M, Soubrier M . Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS One. 2019; 14(8):e0220178. PMC: 6675055. DOI: 10.1371/journal.pone.0220178. View

14.

Morton L, Slager S, Cerhan J, Wang S, Vajdic C, Skibola C . Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014; 2014(48):130-44. PMC: 4155467. DOI: 10.1093/jncimonographs/lgu013. View

15.

Genovese M, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y . Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018; 391(10139):2513-2524. DOI: 10.1016/S0140-6736(18)31116-4. View

16.

Cates M, Donati M, Gillet S, Ustianowski A, Galloway J . Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy. Rheumatology (Oxford). 2017; 57(4):596-605. DOI: 10.1093/rheumatology/kex189. View

17.

Fleischmann R, Genovese M, Enejosa J, Mysler E, Bessette L, Peterfy C . Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019; 78(11):1454-1462. PMC: 6837258. DOI: 10.1136/annrheumdis-2019-215764. View

18.

. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9. View

19.

Winthrop K . The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017; 13(4):234-243. DOI: 10.1038/nrrheum.2017.23. View

20.

Smolen J, Pangan A, Emery P, Rigby W, Tanaka Y, Ignacio Vargas J . Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019; 393(10188):2303-2311. DOI: 10.1016/S0140-6736(19)30419-2. View